RecruitingPhase 2NCT05058638

Effectiveness of Aquamin® in Mitigating Halitosis

Evaluation of Halitosis Using a Multi-Mineral Approach (Aquamin®)

Sponsor

University of Michigan

Enrollment

25 participants

Start Date

Aug 15, 2022

Study Type

INTERVENTIONAL

Conditions

Healthy Halitosis

Summary

The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aquamin for people with halitosis and healthy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAquamin

Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).